-
combination of KRT5 and KRT20 allowed identification of patients with a very poor prognosis (KRT20/KRT5(-), 5-year DSS 0%, p < 0.0001). In silico analysis of the independent MDACC cohorts revealed congruent results (5-year DSS for KRT20 low vs. high: 84% vs. 40%, p = 0.042).
-
Carcinoid-like/labyrinthine pattern of cell arrangement in vimentin/cytokeratin 20 expressing sebaceous neoplasms may represent a morphological phenotype of sebaceous mantles.
-
In our cohort of specimens with equivocal urothelial atypia, very few patients without a prior diagnosis of bladder cancer progressed to diagnostic cancer (1 of 22), suggesting that CK20 and p53 staining results should be interpreted with caution in de novo atypia.
-
results demonstrate the diagnostic value of urinary cytology and confirm CK 20 as an adjunct marker for the diagnosis of urothelial carcinoma.
-
findings of our study imply that sequential staining of CK20 and E-cadherin prevents false-positive classification of BCC. Furthermore, our study demonstrated that p40 exhibits the same staining pattern in BCC, TE, and TB
-
In stomach adenocarcinomas, CDH17 positively stained 64.0% (112 of 175) of tissues, compared to CK20 and CDX2, where staining was observed in only 24.6% (43 of 175) and 46.9% (82 of 175), respectively.
-
results demonstrated upregulation of fibroblast growth factor receptor 1 and CK20 expressions in cancer bladder tissues
-
K20 expression was detected in 6 of 75 patients with triple-negative carcinoma
-
Circulating tumor cell CK20 and survivin expression may effectively predict overall survival in metastic colorectal cancer patients receiving chemotherapy.
-
During postoperative follow-up, serum negative CK20 patients had significantly higher 3-year survival rates than serum positive CK20 patients.
-
Patients with any EGFR, CK19, CK20 or survinin positivity in their peripheral blood obtain less benefit from radiotherapy.
-
Case Report: Merkel cell carcinma that initially demonstrated cytokeratin 20 positivity but lost expression in subsequent brain metastases.
-
Our data show that inclusion of CK20 as a biomarker efficiently improves the detection of CTCs in colorectal cancer patients
-
The present study confirmed that CK14, but not CK20 or CK7, is expressed in urothelial carcinoma with squamous differentiation and squamous cell carcinoma of the urinary bladder.
-
Immunostaining of CDX2 and CK20 provides beneficial information if considering whether to perform an endoscopic papillectomy (EP).
-
High cytokeratin 20 expression is associated with invasive histological phenotype in poorly differentiated colorectal adenocarcinoma.
-
Its association with clinical stage indicates that CK20 might have prognostic value as a marker for detection of circulating CRC cells.
-
The CDX2/CK20 phenotype defines a distinct subgroup of colorectal cancers with microsatellite instability and poor differentiation
-
Data show that lower survival (OS) and disease-free survival (DFS) rates were significantly associated with guanylate cyclase C (GCC) and CK20 mRNA levels.
-
Overexpression of CK20 is associated with early-onset colorectal cancer.
